What's the success rate of tigecycline in infections?

In short:

• In the pivotal trials that led to its approval, tigecycline achieved ≈ 70 % overall clinical cure/response rates in the infections for which it is officially indicated.
• Success rates tend to be high in complicated skin and soft‑tissue infections (cSSSI) and complicated intra‑abdominal infections (cIAI), but are lower for community‑acquired bacterial pneumonia (CABP) and are not recommended for bloodstream infections or serious systemic sepsis because of sub‑therapeutic serum levels.

Below you’ll find a quick snapshot of the evidence and the factors that shape those numbers.

1. Approved Indications & Typical Success Rates

Key point: The “success” numbers above are clinical cure or improvement at the end of therapy. Microbiological eradication rates are slightly lower (≈ 55–60 %) because tigecycline is bacteriostatic.

2. What Determines a “Good” Success Rate?

3. Real‑World Success: What Clinicians See

• Retrospective series (2014‑2022): Clinical cure rates of ≈ 65 % for cSSSI and ≈ 60 % for cIAI in patients with multi‑drug resistant organisms.
• Prospective cohort (2021): 72 % cure in cSSSI but only 50 % in patients with severe sepsis or septic shock.
• Pediatric data: Limited; most children receive tigecycline only after other agents fail, so cure rates hover around 60‑70 %.

Bottom line: In real‑world practice, you can expect a 70 % cure rate in “standard” complicated infections, but this drops to 50‑60 % or lower when infections are severe, involve resistant organisms, or are in patients with significant comorbidities.

4. Caveats & Safety Considerations

5. Practical Take‑Aways

1. Use where evidence is strongest – cSSSI and cIAI.
2. Reserve for MDR organisms – e.g., MRSA, VRE, ESBL‑producing Enterobacteriaceae.
3. Avoid as monotherapy in bloodstream infections; pair with a drug that achieves higher serum levels.
4. Monitor for nausea, liver function, and blood glucose; consider antiemetic prophylaxis.
5. Expect around a 70 % cure rate in the typical setting, but plan for additional or alternative therapy in severe cases.

Bottom line: Tigecycline is a solid choice for many complicated skin, intra‑abdominal, and respiratory infections, delivering about 70 % clinical cure rates in controlled trials. Its performance can dip in more severe, resistant, or bloodstream infections, and safety signals mean it’s used with care in certain patient populations.